{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T04:56:59Z","timestamp":1788411419731,"version":"build-2803163510"},"reference-count":120,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003130","name":"Research Foundation Flanders","doi-asserted-by":"publisher","award":["1S54521N"],"award-info":[{"award-number":["1S54521N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["559839626"],"award-info":[{"award-number":["559839626"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["DFG DE 1546 \/12-1"],"award-info":[{"award-number":["DFG DE 1546 \/12-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["101072895"],"award-info":[{"award-number":["101072895"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ejphar.2026.178591","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T07:57:23Z","timestamp":1769155043000},"page":"178591","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Sleep, wake, and signaling: Functional profiling of orexin agonists and antagonists using newly developed orexin \u03b2-arrestin 2 and miniG\u03b1q recruitment assays"],"prefix":"10.1016","volume":"1015","author":[{"given":"Marie H.","family":"Deventer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9686-8738","authenticated-orcid":false,"given":"Silvia","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4581-5447","authenticated-orcid":false,"given":"Marcus","family":"Angermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Decker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7126-348X","authenticated-orcid":false,"given":"Christophe P.","family":"Stove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2026.178591_bib1","series-title":"Sulfonylamino-Acetic Derivatives and their Use as Orexin Receptor Antagonists","author":"Aissaoui","year":"2004"},{"key":"10.1016\/j.ejphar.2026.178591_bib2","series-title":"Assay Guidance Manual","article-title":"FLIPRTM assays for GPCR and ion channel targets","author":"Arkin","year":"2004"},{"key":"10.1016\/j.ejphar.2026.178591_bib3","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/01.yco.0000165594.60434.84","article-title":"The diagnosis and management of benzodiazepine dependence","volume":"18","author":"Ashton","year":"2005","journal-title":"Curr. Opin. Psychiatr."},{"key":"10.1016\/j.ejphar.2026.178591_bib4","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1124\/pr.117.014381","article-title":"Drugs for insomnia beyond benzodiazepines: pharmacology, clinical applications, and discovery","volume":"70","author":"Atkin","year":"2018","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejphar.2026.178591_bib5","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.neuron.2006.01.016","article-title":"Orexin A in the VTA is critical for the induction of synaptic plasticity and behavioral sensitization to cocaine","volume":"49","author":"Borgland","year":"2006","journal-title":"Neuron"},{"key":"10.1016\/j.ejphar.2026.178591_bib6","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1002\/cmdc.202000453","article-title":"The Quest for the best dual orexin receptor antagonist (Daridorexant) for the treatment of Insomnia disorders","volume":"15","author":"Boss","year":"2020","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejphar.2026.178591_bib7","first-page":"L421","article-title":"Radioligand binding methods: practical guide and tips","volume":"265","author":"Bylund","year":"1993","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.ejphar.2026.178591_bib8","doi-asserted-by":"crossref","first-page":"11476","DOI":"10.1021\/acs.analchem.6b02600","article-title":"Detection and activity profiling of synthetic cannabinoids and their metabolites with a newly developed bioassay","volume":"88","author":"Cannaert","year":"2016","journal-title":"Anal. Chem."},{"key":"10.1016\/j.ejphar.2026.178591_bib9","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1373\/clinchem.2018.289496","article-title":"Activity-Based concept to screen biological matrices for opiates and (Synthetic) opioids","volume":"64","author":"Cannaert","year":"2018","journal-title":"Clin. Chem."},{"key":"10.1016\/j.ejphar.2026.178591_bib10","doi-asserted-by":"crossref","first-page":"5320","DOI":"10.1021\/jm100541c","article-title":"Discovery of the dual orexin receptor antagonist [(7R)-4-(5-Chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia","volume":"53","author":"Cox","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2026.178591_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2022.812359","article-title":"Orexin signaling: a complex, multifaceted process","volume":"16","author":"Dale","year":"2022","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.ejphar.2026.178591_bib12","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1073\/pnas.95.1.322","article-title":"The hypocretins: Hypothalamus-specific peptides with neuroexcitatory activity","volume":"95","author":"De Lecea","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejphar.2026.178591_bib13","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1046\/j.1471-4159.2001.00269.x","article-title":"Visualizing differences in ligand-induced \u03b2-arrestin\u2013GFP interactions and trafficking between three recently characterized G protein-coupled receptors","volume":"77","author":"Evans","year":"2001","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ejphar.2026.178591_bib14","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2207531119","article-title":"Orexin 2 receptor\u2013selective agonist danavorexton improves narcolepsy phenotype in a mouse model and in human patients","volume":"119","author":"Evans","year":"2022","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejphar.2026.178591_bib15","doi-asserted-by":"crossref","DOI":"10.1111\/jsr.13878","article-title":"Orexin 2 receptor-selective agonist danavorexton (TAK-925) promotes wakefulness in non-human primates and healthy individuals","volume":"32","author":"Evans","year":"2023","journal-title":"J. Sleep Res."},{"key":"10.1016\/j.ejphar.2026.178591_bib16","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1007\/s10072-024-07326-w","article-title":"Daridorexant treatment for chronic insomnia: a real-world retrospective single-center study","volume":"45","author":"Fernandes","year":"2024","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.ejphar.2026.178591_bib17","doi-asserted-by":"crossref","first-page":"M99","DOI":"10.1093\/gerona\/50A.2.M99","article-title":"Benzodiazepine use as a cause of cognitive impairment in elderly hospital inpatients","volume":"50A","author":"Foy","year":"1995","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.ejphar.2026.178591_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2025.101962","article-title":"Unraveling the pathophysiology of narcolepsy type 1 through hypothesis-driven and hypothesis-generating approaches","volume":"78","author":"Freeman","year":"2025","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.ejphar.2026.178591_bib19","series-title":"Assay Guidance Manual","article-title":"IP-3\/IP-1 assays","author":"Garbison","year":"2004"},{"key":"10.1016\/j.ejphar.2026.178591_bib20","series-title":"Assay Guidance Manual","article-title":"Phospho-ERK assays","author":"Garbison","year":"2004"},{"key":"10.1016\/j.ejphar.2026.178591_bib21","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s13181-013-0294-y","article-title":"In the zzz Zone: the effects of Z-Drugs on human performance and driving","volume":"9","author":"Gunja","year":"2013","journal-title":"J. Med. Toxicol."},{"key":"10.1016\/j.ejphar.2026.178591_bib22","article-title":"Suvorexant, a novel dual orexin receptor antagonist, for the management of insomnia","volume":"10","author":"Han","year":"2023","journal-title":"Health Psychol Res"},{"key":"10.1016\/j.ejphar.2026.178591_bib23","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1124\/dmd.115.066597","article-title":"The reliability of estimating Ki values for direct, reversible inhibition of cytochrome P450 enzymes from corresponding IC50 values: a retrospective analysis of 343 experiments","volume":"43","author":"Haupt","year":"2015","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejphar.2026.178591_bib24","doi-asserted-by":"crossref","first-page":"3178","DOI":"10.1021\/bi300136h","article-title":"Study of Human Orexin-1 and -2 G-Protein-Coupled receptors with novel and published antagonists by modeling, molecular dynamics simulations, and site-directed mutagenesis","volume":"51","author":"Heifetz","year":"2012","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejphar.2026.178591_bib25","doi-asserted-by":"crossref","first-page":"18059","DOI":"10.1073\/pnas.2002704117","article-title":"Structure-based development of a subtype-selective orexin 1 receptor antagonist","volume":"117","author":"Hellmann","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejphar.2026.178591_bib26","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/s41467-021-21087-6","article-title":"Structures of active-state orexin receptor 2 rationalize peptide and small-molecule agonist recognition and receptor activation","volume":"12","author":"Hong","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejphar.2026.178591_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.medidd.2024.100190","article-title":"On the kinetic features of orexin receptor antagonists at orexin receptors, transduction systems and receptor binding","volume":"22","author":"Hoyer","year":"2024","journal-title":"Med Drug Discov"},{"key":"10.1016\/j.ejphar.2026.178591_bib28","doi-asserted-by":"crossref","first-page":"5453","DOI":"10.1021\/acs.jmedchem.2c01773","article-title":"Design and synthesis of orexin 1 receptor-selective agonists","volume":"66","author":"Iio","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2026.178591_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128555","article-title":"Discovery of orexin 2 receptor selective and dual orexin receptor agonists based on the tetralin structure: switching of receptor selectivity by chirality on the tetralin ring","volume":"60","author":"Iio","year":"2022","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.ejphar.2026.178591_bib30","doi-asserted-by":"crossref","first-page":"5731","DOI":"10.1073\/pnas.1700499114","article-title":"Nonpeptide orexin type-2 receptor agonist ameliorates narcolepsy-cataplexy symptoms in mouse models","volume":"114","author":"Irukayama-Tomobe","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejphar.2026.178591_bib31","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1124\/jpet.122.001449","article-title":"TAK-994, a novel orally available brain-penetrant orexin 2 receptor-selective agonist, suppresses fragmentation of wakefulness and cataplexy-like episodes in mouse models of Narcolepsy","volume":"385","author":"Ishikawa","year":"2023","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejphar.2026.178591_bib32","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1586\/17512433.2014.966813","article-title":"Suvorexant for the treatment of insomnia","volume":"7","author":"Jacobson","year":"2014","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.ejphar.2026.178591_bib33","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.3390\/molecules23112926","article-title":"Investigation of new orexin 2 receptor modulators using in Silico and in vitro methods","volume":"23","author":"Janockova","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.ejphar.2026.178591_bib34","article-title":"16-mer hypocretin-1\/orexin-A in cerebrospinal fluid to diagnose narcolepsy","author":"Jerome","year":"2025","journal-title":"Sleep zsaf237"},{"key":"10.1016\/j.ejphar.2026.178591_bib35","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1146\/annurev-pharmtox-052120-091058","article-title":"Biased agonism: lessons from studies of opioid receptor agonists","volume":"63","author":"Kelly","year":"2023","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.ejphar.2026.178591_bib36","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1111\/bph.16335","article-title":"Bias translation: the final frontier?","volume":"181","author":"Kenakin","year":"2024","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.178591_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12793\/tcp.2024.32.e5","article-title":"Emerging and upcoming therapies in insomnia","volume":"32","author":"Kim","year":"2024","journal-title":"Transl Clin Pharmacol"},{"key":"10.1016\/j.ejphar.2026.178591_bib38","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41398-025-03439-8","article-title":"Comparative efficacy and safety of daridorexant, lemborexant, and suvorexant for insomnia: a systematic review and network meta-analysis","volume":"15","author":"Kishi","year":"2025","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.ejphar.2026.178591_bib39","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1038\/s41467-023-38764-3","article-title":"The G protein preference of orexin receptors is currently an unresolved issue","volume":"14","author":"Kukkonen","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejphar.2026.178591_bib40","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/bph.12324","article-title":"Orexin\/hypocretin receptor signalling cascades","volume":"171","author":"Kukkonen","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.178591_bib41","doi-asserted-by":"crossref","DOI":"10.1159\/000514962","article-title":"Cellular signaling mechanisms of Hypocretin\/Orexin","author":"Kukkonen","year":"2021","journal-title":"Front Neurol Neurosci"},{"key":"10.1016\/j.ejphar.2026.178591_bib42","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1021\/jm030982t","article-title":"Structure\u2212Activity studies of orexin A and orexin B at the human orexin 1 and orexin 2 receptors led to orexin 2 receptor selective and orexin 1 receptor preferring ligands","volume":"47","author":"Lang","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2026.178591_bib43","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1378\/chest.14-1617","article-title":"The pathophysiology of insomnia","volume":"147","author":"Levenson","year":"2015","journal-title":"Chest"},{"key":"10.1016\/j.ejphar.2026.178591_bib44","doi-asserted-by":"crossref","first-page":"70","DOI":"10.2174\/1875397300801010070","article-title":"Comparison on functional assays for Gq-Coupled GPCRs by measuring Inositol Monophospate-1 and intracellular calcium in 1536-Well plate format","volume":"1","author":"Liu","year":"2008","journal-title":"Curr Chem Genomics"},{"key":"10.1016\/j.ejphar.2026.178591_bib45","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/npr2.12105","article-title":"Pharmacological characterization of a novel potent, selective, and orally active orexin 2 receptor antagonist, SDM-878","volume":"40","author":"Maehara","year":"2020","journal-title":"Neuropsychopharmacology Reports"},{"key":"10.1016\/j.ejphar.2026.178591_bib46","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.bcp.2005.12.021","article-title":"Agonist potency differentiates G protein activation and Ca2+ signalling by the orexin receptor type 1","volume":"71","author":"Magga","year":"2006","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.178591_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.175170","article-title":"Orexin system in the ventral tegmental area is implicated in the rewarding properties of methamphetamine","volume":"930","author":"Majidinezhad","year":"2022","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.178591_bib48","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1111\/j.1476-5381.2009.00127.x","article-title":"Biochemical and behavioural characterization of EMPA, a novel high-affinity, selective antagonist for the OX2 receptor","volume":"156","author":"Malherbe","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.178591_bib49","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1124\/mol.109.055152","article-title":"Biochemical and electrophysiological characterization of almorexant, a dual orexin 1 receptor (OX1)\/Orexin 2 receptor (OX2) antagonist: Comparison with selective OX1 and OX2 antagonists","volume":"76","author":"Malherbe","year":"2009","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.178591_bib50","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1124\/mol.110.064584","volume":"78","author":"Malherbe","year":"2010","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.178591_bib51","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s40265-022-01699-y","article-title":"Daridorexant: first approval","volume":"82","author":"Markham","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.ejphar.2026.178591_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104179","article-title":"From orexin receptor agonist YNT-185 to novel antagonists with drug-like properties for the treatment of insomnia","volume":"103","author":"Mezeiova","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejphar.2026.178591_bib53","doi-asserted-by":"crossref","first-page":"6518","DOI":"10.1523\/JNEUROSCI.6506-10.2011","article-title":"Differential roles of orexin Receptor-1 and -2 in the regulation of Non-REM and REM sleep","volume":"31","author":"Mieda","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejphar.2026.178591_bib54","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1073\/pnas.0400590101","article-title":"Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice","volume":"101","author":"Mieda","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejphar.2026.178591_bib55","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1001\/archneur.59.10.1553","article-title":"The role of cerebrospinal fluid hypocretin measurement in the diagnosis of Narcolepsy and other hypersomnias","volume":"59","author":"Mignot","year":"2002","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.ejphar.2026.178591_bib56","doi-asserted-by":"crossref","first-page":"8473","DOI":"10.1038\/s41598-022-12601-x","article-title":"Orexin 2 receptor (OX2R) protein distribution measured by autoradiography using radiolabeled OX2R-selective antagonist EMPA in rodent brain and peripheral tissues","volume":"12","author":"Mitsukawa","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2026.178591_bib57","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-70594-1","article-title":"TAK-861, a potent, orally available orexin receptor 2-selective agonist, produces wakefulness in monkeys and improves narcolepsy-like phenotypes in mouse models","volume":"14","author":"Mitsukawa","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2026.178591_bib58","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00441-006-0284-3","article-title":"GABAA receptor diversity and pharmacology","volume":"326","author":"M\u00f6hler","year":"2006","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.ejphar.2026.178591_bib59","doi-asserted-by":"crossref","DOI":"10.1111\/jsr.13902","article-title":"The orexin story and orexin receptor antagonists for the treatment of insomnia","volume":"32","author":"Muehlan","year":"2023","journal-title":"J. Sleep Res."},{"key":"10.1016\/j.ejphar.2026.178591_bib60","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1080\/17425255.2020.1817380","article-title":"Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders","volume":"16","author":"Muehlan","year":"2020","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.ejphar.2026.178591_bib61","first-page":"655","article-title":"Leading orexin receptor agonist clears phase III for narcolepsy","volume":"24","author":"Mullard","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejphar.2026.178591_bib62","doi-asserted-by":"crossref","first-page":"7931","DOI":"10.1021\/acs.jmedchem.5b00988","article-title":"Design and synthesis of Non-Peptide, selective orexin receptor 2 agonists","volume":"58","author":"Nagahara","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2026.178591_bib63","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0175642","article-title":"Mini-G proteins: novel tools for studying GPCRs in their active conformation","volume":"12","author":"Nehm\u00e9","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2026.178591_bib64","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(99)05582-8","article-title":"Hypocretin (orexin) deficiency in human narcolepsy","volume":"355","author":"Nishino","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2026.178591_bib65","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejphar.2014.07.046","article-title":"Faster, better, stronger: towards new antidepressant therapeutic strategies","volume":"753","author":"O'Leary","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.178591_bib66","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1012622","article-title":"Modulation of sleep behavior in zebrafish larvae by pharmacological targeting of the orexin receptor","volume":"13","author":"Pardon","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.178591_bib67","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/j.bmcl.2010.12.096","article-title":"Discovery of substituted phenyl urea derivatives as novel long-acting \u03b22-adrenoreceptor agonists","volume":"21","author":"P\u00e9rez","year":"2011","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.ejphar.2026.178591_bib68","doi-asserted-by":"crossref","first-page":"15444","DOI":"10.1021\/acs.analchem.9b03104","volume":"91","author":"Pottie","year":"2019","journal-title":"Anal. Chem."},{"key":"10.1016\/j.ejphar.2026.178591_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114251","article-title":"Identification of psychedelic new psychoactive substances (NPS) showing biased agonism at the 5-HT2AR through simultaneous use of \u03b2-arrestin 2 and miniG\u03b1q bioassays","volume":"182","author":"Pottie","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.178591_bib70","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1021\/acschemneuro.3c00267","article-title":"Structure\u2013Activity assessment and In-Depth analysis of biased agonism in a set of phenylalkylamine 5-HT2A receptor agonists","volume":"14","author":"Pottie","year":"2023","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejphar.2026.178591_bib71","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.3390\/ijms23073460","article-title":"The P2Y2 receptor C-Terminal tail modulates but is dispensable for \u03b2-Arrestin recruitment","volume":"23","author":"Pottie","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2026.178591_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.113934","article-title":"Assessment of biased agonism at the A3 adenosine receptor using \u03b2-arrestin and miniG\u03b1i recruitment assays","volume":"177","author":"Pottie","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.178591_bib73","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/PRA.0000000000000690","article-title":"Comparative pharmacology of the 3 marketed dual orexin Antagonists-Daridorexant, lemborexant, and suvorexant-part 2. Principal drug metabolizing enzyme, drug-drug interactions, and effects of liver and renal impairment on metabolism","volume":"29","author":"Preskorn","year":"2023","journal-title":"J. Psychiatr. Pract."},{"key":"10.1016\/j.ejphar.2026.178591_bib74","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/PRA.0000000000000672","article-title":"Comparative pharmacology of the 3 marketed dual orexin Antagonists\u2014Daridorexant, lemborexant, and suvorexant: part 1: pharmacokinetic profiles","volume":"28","author":"Preskorn","year":"2022","journal-title":"J. Psychiatr. Pract."},{"key":"10.1016\/j.ejphar.2026.178591_bib75","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nrd3024","article-title":"Teaching old receptors new tricks: biasing seven-transmembrane receptors","volume":"9","author":"Rajagopal","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejphar.2026.178591_bib76","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2013.00254","article-title":"Dual orexin receptor antagonists show distinct effects on locomotor performance, ethanol interaction and sleep architecture relative to gamma-aminobutyric acid-A receptor modulators","volume":"7","author":"Ramirez","year":"2013","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.ejphar.2026.178591_bib77","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1021\/acs.jmedchem.9b01787","article-title":"Comparison of orexin 1 and orexin 2 ligand binding modes using X-ray crystallography and computational analysis","volume":"63","author":"Rappas","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2026.178591_bib78","doi-asserted-by":"crossref","DOI":"10.1111\/jsr.14035","article-title":"The European Insomnia Guideline: an update on the diagnosis and treatment of insomnia 2023","volume":"32","author":"Riemann","year":"2023","journal-title":"J. Sleep Res."},{"key":"10.1016\/j.ejphar.2026.178591_bib79","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.smrv.2009.04.002","article-title":"The hyperarousal model of insomnia: a review of the concept and its evidence","volume":"14","author":"Riemann","year":"2010","journal-title":"Sleep Med. Rev."},{"key":"10.1016\/j.ejphar.2026.178591_bib80","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ejphar.2018.09.003","article-title":"Pharmacological characterization of the orexin\/hypocretin receptor agonist Nag 26","volume":"837","author":"Rinne","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.178591_bib81","doi-asserted-by":"crossref","unstructured":"Robinson CL, Supra R, Downs E, et al. Daridorexant for the treatment of insomnia. Health Psychol Res 10:37400. https:\/\/doi.org\/10.52965\/001c.37400.","DOI":"10.52965\/001c.37400"},{"key":"10.1016\/j.ejphar.2026.178591_bib82","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1007\/s00213-021-05954-0","article-title":"Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia","volume":"238","author":"Roch","year":"2021","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.ejphar.2026.178591_bib83","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s40263-024-01150-8","article-title":"Therapeutic use of \u03b3-Hydroxybutyrate: history and clinical utility of oxybates and considerations of Once- and twice-nightly dosing in Narcolepsy","volume":"39","author":"Roth","year":"2025","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ejphar.2026.178591_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2023.171051","article-title":"The present and future of synthetic orexin receptor agonists","volume":"167","author":"Saitoh","year":"2023","journal-title":"Peptides"},{"key":"10.1016\/j.ejphar.2026.178591_bib85","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0167-0115(99)00076-2","article-title":"Orexins and orexin receptors: implication in feeding behavior","volume":"85","author":"Sakurai","year":"1999","journal-title":"Regul. Pept."},{"key":"10.1016\/j.ejphar.2026.178591_bib86","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/nrn2092","article-title":"The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness","volume":"8","author":"Sakurai","year":"2007","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.ejphar.2026.178591_bib87","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0092-8674(00)80949-6","article-title":"Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior","volume":"92","author":"Sakurai","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2026.178591_bib88","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1055\/s-0043-1770805","article-title":"Daridorexant, a recently approved Dual Orexin Receptor Antagonists (DORA) in treatment of insomnia","volume":"16","author":"Sarathi Chakraborty","year":"2023","journal-title":"Sleep Sci"},{"key":"10.1016\/j.ejphar.2026.178591_bib89","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1146\/annurev-pharmtox-010510-100528","article-title":"Orexin receptors: pharmacology and therapeutic opportunities","volume":"51","author":"Scammell","year":"2011","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.ejphar.2026.178591_bib90","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40265-020-01276-1","article-title":"Lemborexant: first approval","volume":"80","author":"Scott","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.ejphar.2026.178591_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.npep.2023.102335","article-title":"Orexin receptor antagonists in the pathophysiology and treatment of sleep disorders and epilepsy","volume":"99","author":"Sheibani","year":"2023","journal-title":"Neuropeptides"},{"key":"10.1016\/j.ejphar.2026.178591_bib92","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.tips.2011.05.002","article-title":"\u03b2-arrestin-mediated receptor trafficking and signal transduction","volume":"32","author":"Shenoy","year":"2011","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejphar.2026.178591_bib93","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1038\/sj.bjp.0703257","article-title":"The hypocretins are weak agonists at recombinant human orexin-1 and orexin-2 receptors","volume":"129","author":"Smart","year":"2000","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.178591_bib94","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/00004850-199909000-00004","article-title":"Tolerance and rebound insomnia with rapidly eliminated hypnotics: a meta-analysis of sleep laboratory studies","volume":"14","author":"Soldatos","year":"1999","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.ejphar.2026.178591_bib95","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.bcp.2018.01.008","article-title":"Molecular dissection of the human A3 adenosine receptor coupling with \u03b2-arrestin2","volume":"148","author":"Storme","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.178591_bib96","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.str.2017.11.005","article-title":"Crystal structures of human orexin 2 receptor bound to the subtype-selective antagonist EMPA","volume":"26","author":"Suno","year":"2018","journal-title":"Structure"},{"key":"10.1016\/j.ejphar.2026.178591_bib97","doi-asserted-by":"crossref","first-page":"ITC33","DOI":"10.7326\/AITC202103160","article-title":"Insomnia","volume":"174","author":"Sutton","year":"2021","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ejphar.2026.178591_bib98","doi-asserted-by":"crossref","first-page":"6035","DOI":"10.2147\/DDDT.S73224","article-title":"Profile of suvorexant in the management of insomnia","volume":"9","author":"Sutton","year":"2015","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.ejphar.2026.178591_bib99","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/j.bmc.2015.01.044","article-title":"Discovery and in vitro and in vivo profiles of N-ethyl-N-[2-[3-(5-fluoro-2-pyridinyl)-1H-pyrazol-1-yl]ethyl]-2-(2H-1,2,3-triazol-2-yl)-benzamide as a novel class of dual orexin receptor antagonist","volume":"23","author":"Suzuki","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejphar.2026.178591_bib100","doi-asserted-by":"crossref","DOI":"10.3389\/fnbeh.2014.00182","article-title":"Orexin receptor antagonist-induced sleep does not impair the ability to wake in response to emotionally salient acoustic stimuli in dogs","volume":"8","author":"Tannenbaum","year":"2014","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.ejphar.2026.178591_bib101","doi-asserted-by":"crossref","first-page":"603","DOI":"10.5665\/sleep.5536","article-title":"Inhibition of orexin signaling promotes sleep yet preserves salient arousability in monkeys","volume":"39","author":"Tannenbaum","year":"2016","journal-title":"Sleep"},{"key":"10.1016\/j.ejphar.2026.178591_bib102","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.bbapap.2003.11.029","article-title":"PKA: a portrait of protein kinase dynamics","volume":"1697","author":"Taylor","year":"2004","journal-title":"Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics"},{"key":"10.1016\/j.ejphar.2026.178591_bib103","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0896-6273(00)00058-1","article-title":"Reduced number of hypocretin neurons in Human Narcolepsy","volume":"27","author":"Thannickal","year":"2000","journal-title":"Neuron"},{"key":"10.1016\/j.ejphar.2026.178591_bib104","doi-asserted-by":"crossref","unstructured":"Thomaz TG, McBenedict B, Meireles DK, et al. Treatment of Narcolepsy type 1 with orexin: a systematic review. Cureus 16:e76692. https:\/\/doi.org\/10.7759\/cureus.76692.","DOI":"10.7759\/cureus.76692"},{"key":"10.1016\/j.ejphar.2026.178591_bib105","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1124\/jpet.117.241596","article-title":"The use of physiology-based pharmacokinetic and pharmacodynamic modeling in the discovery of the dual orexin receptor antagonist ACT-541468","volume":"362","author":"Treiber","year":"2017","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.ejphar.2026.178591_bib106","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0178526","article-title":"Orexin receptor agonist Yan 7874 is a weak agonist of orexin\/hypocretin receptors and shows orexin receptor-independent cytotoxicity","volume":"12","author":"Turku","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2026.178591_bib107","doi-asserted-by":"crossref","first-page":"zsab224","DOI":"10.1093\/sleep\/zsab224","article-title":"Abuse potential assessment of the new dual orexin receptor antagonist daridorexant in recreational sedative drug users as compared to suvorexant and zolpidem","volume":"45","author":"Ufer","year":"2022","journal-title":"Sleep"},{"key":"10.1016\/j.ejphar.2026.178591_bib108","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2165\/00023210-200418050-00003","article-title":"Residual effects of hypnotics","volume":"18","author":"Vermeeren","year":"2004","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ejphar.2026.178591_bib109","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.5665\/sleep.5168","article-title":"On-the-Road driving performance the morning after bedtime use of suvorexant 20 and 40 mg: a Study in non-elderly healthy volunteers","volume":"38","author":"Vermeeren","year":"2015","journal-title":"Sleep"},{"key":"10.1016\/j.ejphar.2026.178591_bib110","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2018.00220","article-title":"The Orexin\/Receptor System: molecular mechanism and therapeutic potential for neurological diseases","volume":"11","author":"Wang","year":"2018","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.ejphar.2026.178591_bib111","series-title":"Assay Guidance Manual","article-title":"Measurement of \u03b2-Arrestin recruitment for GPCR targets","author":"Wang","year":"2004"},{"key":"10.1016\/j.ejphar.2026.178591_bib112","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.3390\/ijms20071686","article-title":"Distinct dopamine D2 receptor antagonists differentially impact D2 receptor oligomerization","volume":"20","author":"Wouters","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2026.178591_bib113","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1021\/acsptsci.9b00069","article-title":"Assessment of biased agonism among distinct synthetic cannabinoid receptor agonist scaffolds","volume":"3","author":"Wouters","year":"2020","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.ejphar.2026.178591_bib114","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s11920-022-01357-w","article-title":"Orexin receptor antagonists and insomnia","volume":"24","author":"Wu","year":"2022","journal-title":"Curr. Psychiatry Rep."},{"key":"10.1016\/j.ejphar.2026.178591_bib115","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1175372","article-title":"Different doses of dual orexin receptor antagonists in primary insomnia: a Bayesian network analysis","volume":"14","author":"Xue","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.178591_bib116","series-title":"Small-Molecule Agonists for type-2 Orexin Receptor","author":"Yanagisawa","year":"2010"},{"key":"10.1016\/j.ejphar.2026.178591_bib117","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1038\/s41467-022-30601-3","article-title":"Molecular mechanism of the wake-promoting agent TAK-925","volume":"13","author":"Yin","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejphar.2026.178591_bib118","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1021\/acs.jmedchem.5b00217","article-title":"Discovery of (1R,2S)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropanecarboxamide (E2006): A Potent and Efficacious Oral Orexin Receptor Antagonist","volume":"58","author":"Yoshida","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2026.178591_bib119","doi-asserted-by":"crossref","first-page":"8806","DOI":"10.1021\/acs.jmedchem.1c00841","article-title":"Discovery of arylsulfonamides as dual orexin receptor agonists","volume":"64","author":"Zhang","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2026.178591_bib120","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.3390\/molecules27186041","article-title":"A comprehensive review of daridorexant, a dual-orexin receptor antagonist as new approach for the treatment of insomnia","volume":"27","author":"Ziemich\u00f3d","year":"2022","journal-title":"Molecules"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926000737?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926000737?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T17:46:44Z","timestamp":1777398404000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299926000737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":120,"alternative-id":["S0014299926000737"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.178591","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sleep, wake, and signaling: Functional profiling of orexin agonists and antagonists using newly developed orexin \u03b2-arrestin 2 and miniG\u03b1q recruitment assays","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.178591","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"178591"}}